← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #49 OF 1,000 MOST-CITED

Equipment Design, Size and Location

FDA cited this observation 393 times across 358 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs393
BY FISCAL YEAR
FY202622
FY202567
FY202468
FY202346
FY202243
FY202118
FY202029
FY201944
FY201839
FY201717

How FDA worded it — real examples

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.

My CHS Rx, Inc. · Hauppauge, New York · Drugs · 2026-06-05

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.

I 3 PHARMACEUTICALS, LLC · Warminster, Pennsylvania · Drugs · 2026-05-22

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and of adequate size to facilitate operations for its intended use.

Ajanta Pharma Ltd. · Paithan · Drugs · 2026-04-21

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Nova Biologicals, Inc. · Conroe, Texas · Drugs · 2026-04-06

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Baxter Healthcare Corporation · Round Lake, Illinois · Drugs · 2026-04-02

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.

Eosera, Inc. · Fort Worth, Texas · Drugs · 2026-03-20

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →